According to CEO Hubert Koster, the financing will allow the company to expand its Capture Compound Mass Spectrometry technology into additional markets and "execute several large pharma partnerships at the same time."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.